v, With the cooperation of 60 neurosurgieal centers in Japan, a prospective randomized placebo-controlled double-blind trial of a new calcium antagonist AT877 (hexahydro-l-(5-isequinolinesulfonyl)-1 H-1,4-diazepine hydrochloride, or fasudil hydrochloride) was undertaken to determine the drug's effect on delayed cerebral vasospasm in patients with a ruptured cerebral aneurysm. A total of 276 patients, who underwent surgery within 3 days after subaraehnoid hemorrhage (SAH) of Hunt and Hess Grades I to IV, were entered into the study. Nine patients were excluded because of protocol violation. The remaining 267 patients received either 30 mg AT877 or a placebo (saline) by intravenous injection over 30 minutes, three times a day for 14 days following surgery. Demographic and clinical data were well matched between the two groups.
D
ELAYED cerebral ischemia associated with cerebral vasospasm is still the leading cause of poor postoperative outcome in patients with a ruptured intracranial aneurysm) 6.~7 Nimodipine has been the only calcium antagonist that has been shown to improve patient outcome in prospective placebo-controlled double-blind trials. L~4' 2~ However, nimodipine did not affect the severity of angiographically observed vasospasm.
The drug AT877 (hexahydro-l-(5-isoquinolinesulfonyl)-1H-l,4-diazepine hydrochloride, or fasudil hydrochloride) is a new calcium antagonist that has a different mechanism of action from calcium entry blockers such as nimodipine or nicardipine (it is identical to HA1077). It inhibits the action of the free intracellular calcium ion) and also inhibits protein kinases A, G, and C and myosin light-chain kinase, the final common pathway of smooth-muscle contraction. 4 .t2 It has been shown that AT877 antagonizes the cerebral vasoconstrictor effect of endothelin? Intravenous AT877 dilates spastic cerebral arteries in the canine two-hemorrhage modelfl '3~ Our previous report of an open clinical trial with AT877 suggested that it reduced angiographically verified vasospasm or cerebral infarction in a dose-dependent manner? s
We now report the results of a prospective randomized placebo-controlled double-blind trial of AT877 in patients with aneurysmal subarachnoid hemorrhage (SAH) . The endpoints of the trial were clinical outcome at I month, occurrence of angiographically determined vasospasm, incidence of symptomatic vasospasm, and incidence and extent of low-density areas on computerized tomography (CT) scans associated with vasospasm.
Materials and Methods

Patient Selection
Sixty Japanese neurosurglcal units joined the trial. There were 276 patients entered into the trial; all were classified with Hunt and Hess n Grades I to IV and underwent surgery for ruptured aneurysms within 3 days after SAH. For the purpose of the trial, patients with severe SAH were selected whenever possible and the entry of patients with minor SAH was restricted. Patients with the following conditions were not admitted to the trial: a history of severe cerebrovascular disease, moyamoya disease, giant aneurysm, recent previous SAH, and severe cardiopulmonary, hepatorenal, or metabolic diseases (such as diabetes mellitus).
Treatment Groups
Patients were randomly assigned by the controller (M.N.) to the treatment or placebo group by using separate randomization lists for each center, balanced in blocks of four. Asahi Chemical Industry Company and Toyo Jozo Company supplied the ampules containing AT877 (30 rag, dissolved in 2 ml saline) or placebo (2 ml saline), respectively. The code was kept by the controller until the end of the trial and after all outcomes had been determined.
Both AT877 and saline were dissolved in 100 ml of saline administered intravenously over 30 minutes three times a day. Drug or placebo treatment was started within 24 hours after aneurysm surgery and was continued for 14 consecutive days. Patients or their next of kin were given an explanation of the nature of the drug and the purpose of the trial, and consent was obtained for each patient prior to entering the trial.
Clinical and Radiological Investigations
Patients were followed daily for 30 days after SAH. Deterioration in level of consciousness, appearance of motor weakness, sensory deficit, or aphasia was recorded as symptomatic vasospasm if there was no other explanation in the postoperative period. Postoperative angiograms were obtained between Days 5 and 21. Angiographically demonstrated vasospasm was classified into four grades: none; mild (minimal or mild change in vessel lumen); moderate (between mild and severe); and severe (threadlike and diffuse narrowing of vessels).
Computerized tomography scans were usually obtained four times; on admission, immediately after surgery, between 1 and 2 weeks after SAH, and at 1 month after SAH. Low-density areas on postoperative CT scans (between Days 5 and 42) were classified into five grades: none; mild, or small lacunar-like low-density areas less than 1 cm in diameter (corrected for magnification); moderate, or low-density areas greater than 1 cm but limited to territories of branches of a major cerebral artery; severe, or low-density areas extending to the entire territory of a major cerebral artery; and larger. Participating neurosurgeons were asked to decide on the most likely cause of low-density areas visible on postoperative CT scans. Larger low-density areas (due to vasospasm) between the latter two CT scans (1 or 2 weeks after the SAH, and at 1 month) were selected and analyzed. The CT scans and anglograms were initially assessed by the participating neurosurgeons. They were then independently assessed by a neuroradiologist. If opinions differed, the radiograms were judged by a review committee of six neurosurgeons (M.S., Y.S., I.S., T.S., T.T., and I.N.) prior to breaking the code. Clinical outcome was assessed at 1 month after the hemorrhage according to the Glasgow Outcome Scale (GOS).t5
The primary endpoints for the determination of efficacy of the drug were defined as: 1) reduction of either incidence or severity of angiographic vasospasm; 2) reduction of incidence and size of low-density area due to vasospasm on the postoperative CT seam; 3) reduction of incidence of symptomatic vasospasm; and 4) poor outcome (moderate or severe disability, persistent vegetative state, or death) due to delayed neurological deficits from vasospasm.
Other treatments for vasospasm such as hypertensivehypervolemie therapy, low-molecular weight dextran, glycerol, and mannitol were allowed. However, the following drugs were prohibited as they are recognized as antivasospastic drugs in Japan: thromboxane A: synthetase inhibitor (OKY-046), platelet inhibitor (ticlopidine), and a brain-protecting drug (nizofenone). The use of barbiturate coma therapy was also prohibited.
Statistical A nalysis
Sample size determination was based on an expected incidence of delayed ischemic neurological deficits due to vasospasm of 35% in the placebo group and 15% in the AT877 group. 28 It was calculated that 150 patients would be required in each group to have an 80% chance of detecting a reduction in delayed ischemic deficits (that is, a GOS outcome of moderate disability or worse) using a significance level of p = 0.05. Comparison of demographic data, clinical variations, and radiological and clinical assessments between the treatment groups was done by the chi-squared test with Yates' continuity correction. The effect of AT877 on blood pressure was assessed using a two-tailed paired t-test
Results
Demographic and Clinical Data
Between June, 1989, and June, 1990, 276 patients were entered into the trial. Nine patients (3%) were excluded because of violation of the treatment protocol: delayed surgery (one AT877 and two placebo patients), previous severe cerebrovascular disease (one patient in each group), vasospasm on admission (one AT877 patient), use of ticlopidine (one AT877 patient), and barbiturate coma (one patient in each group). All of the remaining 267 patients were included in the analysis. The demographic and background data of the patients, including age, sex, severity of SAH, location of aneurysm, and timing of surgery, were compared and no statistically significant differences were found between the treatment groups ( Table 1 ). The intention was to recruit more patients with severe SAH on initial CT scans. Therefore, 101 (77%) of the 131 patients in the AT877 group and 100 (74%) of the 136 in the placebo group were classified as Grade 3 according to Fisher, et al.; R 20 (15%) of the AT877 group and 17 (13%) of the placebo group were classified as Grade 4 with an intracerebral hematoma. The number of pa- (27) 33 (35) 24 (25) 12 (13) 95 (38) placebo 17 (18) 20 (21) 40 (42) 19 (20) 
Angiographically Demonstrated Vasospasm
Postoperative angiography was performed between Days 5 and 21 in 73% of the patients taking AT877 (12.8 _+ 4.1 days post-hemorrhage) and in 71% of the patients taking the placebo (12.3 _+ 3.9 days posthemorrhage). The number of patients with moderate or severe angiographically demonstrated vasospasm was significantly decreased by 38% with AT877 (placebo group 61% (59 of 96 cases), AT877 group 38% (36 of 95 cases), x 2 = 9.684, degrees of freedom (dt) = 1, p = 0.0023) ( Table 2) .
Symptomatic Vasospasm
Neurological deterioration, either temporary or permanent, was considered to be due to vasospasm when all other potential causes such as surgery, hydrocephalus, intracranial rebleeding, seizure, infection, cardiopulmonary dysfunction, electrolyte imbalance, and metabolic disturbances were excluded. The number of patients with symptomatic vasospasm was significantly decreased by 30% with AT877 (placebo group 50% (64 of 129 cases), AT877 group 35% (43 of 123 cases), x 2 = 4.950, df = 1, p = 0.024) ( Table 3) . Treatment with AT877 also delayed the appearance of symptomatic vasospasm. The average time to appearance of symptomatic vasospasm was 8.2 _+ 3.3 days and 7.3 _+ 2.6 days for the AT877 and the placebo groups, respec- tivcly. However, this delay in the appearance of vasospasm in the AT877 group did not reach statistical significance (p = 0.06).
Low-Density Areas on CT Scans
The cause of low-density areas on CT scans that appeared de novo postoperatively was examined. When all other causes of low-density areas were excluded, for example, operative (brain retraction and occlusion of arteries or veins), low-density areas around a hematoma, and periventricular lucency in hydrocephalic patients, then such low-density areas were considered to be due to vasospasm. The occurrence of low-density areas due to vasospasm of more than moderate severity was significantly decreased with AT877 by 58% from 38% (35 of 93 cases) of the placebo group to 16% (15 of 95 cases) of the AT877 group (x ~ = 10.376, df = 1, p = 0.0013) ( Table 4) . Statistical significance was still valid when the whole group of patients was included (50% of the placebo group, 30% of the AT877 group, X 2 = 9.779, df = 1, p = 0.0022) ( Table 4) .
Clinical Outcome
Treatment with AT877 significantly reduced the number of patients with poor GOS outcomes (moderate and severe disability, persistent vegetative state and death) due to vasospasm at 1 month after SAH by 54% from 26% (29 of 110 cases) of the placebo group to 12% (12 of 99 cases) of the AT877 group (X 2 = 5.830, df = 1, p = 0.0152) ( Table 5 ). However, the beneficial effect of AT877 was masked when other causes of poor outcome (direct effect of SAH, hydrocephalus, surgery, intracranial hemorrhage including rebleeding from aneurysm, medical diseases, and infection) were included. Among the primary causes of clinical deterioration, only the incidence of vasospasm was significantly different between the treatment groups (Table 6 )
Adverse Reactions
It was found that AT877 slightly lowered the systemic arterial blood pressure by 2 mm Hg (p < 0.05, paired t-tes0 over the first 15 minutes of infusion, but this resolved. There was no difference between the treatment groups in the occurrence of any of the other adverse reactions. Intracranial bleeding including re-M. Shibuya, el al. i" For simplicity, the severe and larger grades are combined. ~t Significant differences: vasospasm group, p = 0.0013; all causes, p = 0.0022.
bleeding from the aneurysm site, intracerebral hematoma, and epidural hematoma occurred in 15 (6%) of 267 patients: seven of the AT877 group and eight in the placebo group. Abnormalities in laboratory blood tests occurred in 23 patients (9%): nine in the AT877 group and 14 in the placebo group. Other side effects (facial flushing, headache, and constipation) common to other calcium antagonists did not occur in patients taking AT877.
Discussion
Pharmacokinetics of A T877
The calcium antagonist properties of AT877 are quite different from those of calcium entry blockers such as nimodipine, nifedipine, or nicardipine. It selectively inhibits intracellular calcium ion activity, 3 is water-soluble, and is lipid-insoluble. In our previous animal experiments, intravenous AT877 produced dilation of spastic canine basilar arteries, 29"3~ an effect that was not seen with other calcium antagonists. 6'~821'3' A high selectivity of AT877 for intracranial arteries compared with extracranial arteries has been shown 29 and cardiac suppression is minimal. This may explain why it dilates cerebral arteries at a dose that causes minimal hypotension. It also inhibits protein kinases A, G, and C and myosin light-chain kinase which are essential components in smooth-muscle contraction. This action clearly differentiates AT877 from other calcium antagonists."~2 Although AT877 is cleared quickly from the blood with a half-life of less than 15 minutes, its hydroxylated metabolite, hexahydro-1-( l-hydroxy-5-isoquinolinesulfonyl)-lH-l,4-diazepine, also shows spasmolytic activity. A detectable amount of the metabolite remains in the blood for as long as 8 hours after infusion (unpublished data). It is conceivable that part of the spasmolyric activity seen with AT877 is derived from this metabolite, which may explain the effectiveness of intermittent administrations of AT877 in the present trial. 
Effects on Clinical Outcome
The effectiveness of the calcium antagonist nimodipine on delayed ischemic neurological deficits due to cerebral vasospasm has been well established from resuits of several placebo-controlled double-blind studies) '~4'2~
In 1983, Allen, et al., l first demonstrated a significantly better result with nimodipine in goodgrade patients with SAH when a subgroup of patients with ischemic neurological deficits attributed to raspspasm was defined. Delayed surgery was performed in most of these patients. Auer, et al.: and Ljunggren, et al., 19 suggested in open studies that nimodipine was useful in patients who underwent surgery early. Subsequently, in placebo-controlled double-blind trials, Philippon, et al., 2~ Mee, et al., 2~ Jan, et al.,'" Petruk, et aL, z30hman and Heiskanen, n and Pickard, et aL, 25 showed significantly better clinical outcomes in patients receiving nimodipine. The beneficial effect of nimodipine seems to be universal despite the considerable variability between the trials over details of patients' background and alternative treatment modalities such as timing of surgery, pre-and postoperative drug treatments including hypervolemic-hypertensive therapy, and the use of cisternal cerebrospinal fluid drainage. Haley, et al., ~t reported from a placebo-controlled double-blind trial that nicardipine significantly reduced the incidence of symptomatic vasospasm by 30%.
The effect of AT877 on clinical outcome in patients with aneurysmal SAH in the present report is comparable to that of nimodipine. It was found that AT877 significantly reduced the number of patients with poor results (moderate disability or worse) due to vasospasm from 26% (placebo)to 12% (AT877, p = 0.015) ( Table  5 ). This beneficial effect of AT877 may consist of two components: first, protection of the ischemic brain from calcium overload, 26 and second, the vasodilating effect of spastic cerebral arteries 29.3~ as seen on cerebral angiograms and also on the small neuroradiologically invisible arterioles. The effect of AT877 is characterized by its ability to alter vessel caliber, as demonstrated on angiograms. Other calcium antagonists have failed to change the angiographic appearance of vasospasm. However, the beneficial effect of AT877 is masked and the difference becomes insignificant when all patients who deteriorated from causes other than vasospasm are taken into consideration. This is not surprising since AT877 will not significantly influence clinical deterioration due to the direct effect of SAH and rebleeding. A trial with a larger number of patients (Pickard, et al., 2s calculated this number to be 540) may be needed to obtain statistical significance in the whole group of patients.
Effect on Angiographically Demonstrated Vasospasm
Most calcium antagonists have failed to demonstrate a vasodilatory effect in the chronic phase of vasospasm either experimentally or in patients treated with intravenous or oral forms. 6:s'2L~ Although Frazee, et al., 9 have shown that diltiazem prevents vasospasm in a dog model, no data from a double-blind clinical trial are yet available. A strong vasodilatory effect of AT877 on chronic cerebral vasospasm by intravenous infusion has been shown in both dogs and humans. 2B-~~ The minimum effective dose of AT877 was 0.5 mg/kg by a 30-minute intravenous infusion in dogs. 29 In humans, a 10-to 60-mg 30-minute infusion of AT877 showed a dose-dependent decrease of moderate and severe angiographically observed vasospasm. 2s Higher doses, over the 30 mg used in the present trial, might have further decreased vasospasm, but the adverse effects with higher doses must be evaluated carefully. Low score defined as moderate disability or worse on the Glasgow Outcome Scale (GOS)) s Among the 35% of patients with symptomatic vasospasm in the AT877 group, only one-third (13% of the total) had severe disabilities (moderate disability or worse). The remaining two-thirds of patients had either transient or mild deficits. By comparison, in the placebo group, one-half of the patients with symptomatic vasospasm had severe disabilities. In other words, AT877 reduced not only the incidence of symptomatic vasospasm by 30%, but also its severity (Tables 3 and 5 ). The delay in appearance of symptomatic vasospasm by 1 day in the AT877 group (from Day 7.3 to Day 8.2, p = 0.06) also suggests an antivasospastie effect of the drug. Such a delay in the appearance of symptomatic vasospasm was also seen in patients with cisternal drainage compared to those without (unpublished dam).
Infarction as Revealed on CT Scans
It was found that AT877 reduced by 58% the incidence of moderate or severe low-density areas due to vasospasm seen on postoperative CT scans. This cerebral protective effect of AT877 is significant even when all of the low-density areas on the postoperative CT scans, irrespective of cause, are included (Table 4) . Piekard, et al.,2s noted that cerebral ischemia could be caused not only by angiographically detected vasospasm, but also by such factors as raised intracranial pressure, hypotension, hypoxia, hypovolemia, hyponatremia, and advancing age. Our results suggest that AT877 protects the ischemic brain regardless of the cause of neurological deterioration. The ability of nimodipine to protect the brain from isehemia is well known, t~ Although AT877 was started postoperatively in all cases, preoperative administration should also be assessed, as it may protect the brain from intraoperative injuries and may further improve patient outcome. Experiments from our laboratory and others have demonstrated that AT877 significantly reduced delayed M. Shibuya, et al. neuronal death in gerbils following ischemic injury. It has been found that AT877 increased regional cerebral blood flow in control rats as measured by ~4C-iodoantipyrine autoradiography. These results will be reported separately.
There were no serious adverse effects with the present dosage and routes of administration of AT877. However, higher doses may further lower blood pressure especially in dehydrated patients. Since AT877 increases urine output by increasing renal blood flow, daily water balance must be carefully checked and patients should be maintained normovolemic. Any decrease in blood pressure by AT877 can be successfully corrected by the intravenous administration of crystalloids or dopamine. A multimodality approach to the treatment of vasospasm may also include intracisternal injection of tissue plasminogen activator, 7' 27 hypervolemic-h~ertensive therapy, and administration of antiplatelet agents.
Conclusions
The intravenous administration of 30 mg of AT877 three times a day for 14 days to patients who underwent surgery within 3 days after SAH from a ruptured intracranial aneurysm significantly reduced by 54% the number of patients with a poor clinical result due to vasospasm. In addition, AT877 significantly reduced the incidence of angiographieally detected vasospasm by 38%, symptomatic vasospasm by 30%, and the lowdensity area on CT scans due to vasospasm by 58% ( Table 7 ). The ability of AT877 to reverse angiographically detected vasospasm has not been reported for the other calcium antagonists and confirms its strong spasmolytic effect. The greater reduction in low-density areas on CT scans despite angiographically determined vasospasm may suggest that AT877, like other calcium antagonists, protects cell membranes from isehemie injury. No serious adverse side effects were seen. This study found AT877 to be a safe and useful drug for patients with a ruptured cerebral aneurysm.
